Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Express News | A rare wave of suspensions! More than 60 Hong Kong stocks announced suspension of trading on the same day
Peijia Healthcare (09996.HK) was suspended due to financial asset evaluation, business operations were normal, and unaudited performance was improving
On April 2, Peijia Healthcare (09996.HK) issued an announcement stating that since the company is discussing the valuation of financial assets with the auditor (initial investment cost is HK$80 million) and is still awaiting certain information and supporting documents, the company will delay issuing the annual results announcement and suspend stock trading from April 2, pending publication of the audited annual results. It is worth noting that the 2023 annual results release deadline set by the Hong Kong Stock Exchange last Thursday has passed. Pegasus Healthcare is only one of many companies, such as Country Garden, Novartis Health, Hongjiu Fruit, and Yida China, which failed to release the audited results announcements in a timely manner. Moreover, it is only because
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
Peijia Medical-B (09996.HK) suspended trading this morning
On April 2, Gelonghui Medical-B (09996.HK) announced that trading of the company's shares will be suspended from 9:00 a.m. today (2/4/2024).
PEIJIA-B: DELAY IN PUBLICATION OF 2023 ANNUAL RESULTS AND SUSPENSION OF TRADING
Peijia Medical Narrows 2023 Loss as Revenue Jumps 76%
Peijia Medical (HKG:9996) narrowed 2023 loss attributable to owners to 392.5 million yuan, or 0.58 yuan per share, from 407.8 million yuan, or 0.61 yuan per share, the year earlier. Revenue rose year
Peijia Medical-B (09996) announced 2023 unaudited results. Shareholders' losses of 393 million yuan narrowed by 3.7% year-on-year
According to the Zhitong Finance App, Peijia Medical-B (09996) disclosed the 2023 unaudited annual results announcement. The company achieved revenue of 441 million yuan (RMB, same below) during the reporting period, an increase of 75.9% over the previous year. Gross profit of 325 million yuan, an increase of 84.7% year over year. The company's owners should have accounted for a loss of 393 million yuan, and the loss narrowed by 3.7% year-on-year. Loss of $0.58 per share. During the reporting period, the neurological intervention business achieved revenue of 256 million yuan, an increase of 78.1% over the previous year, which greatly exceeded expectations. The gross profit of this business increased 83.4% year over year to 166 million yuan. The main reason for generating revenue is
PEIJIA-B: UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Insider Sellers Might Regret Selling Peijia Medical Shares at a Lower Price Than Current Market Value
Peijia Medical Limited's (HKG:9996) stock price has dropped 15% in the previous week, but insiders who sold CN¥11m in stock over the past year have had less luck. Insiders might have been better off
Peijia Medical-B (09996.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 15 | Pegasus Medical-B (09996.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
PEIJIA-B: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional pr
Peijia Medical's 2023 Profit to Jump Up to 79.4%
Peijia Medical (HKG:9996) expects to record revenue of between 430 million yuan and 450 million yuan for 2023, jumping up to 79.4% from 250.8 million yuan in the prior year. The provider of interventi
Selected Announcements | CNOOC's production target this year exceeds 700 million barrels; Fuyao Glass plans to invest 5.75 billion yuan in construction projects
Guangshen Railway Co., Ltd. made a profit. It is expected to achieve net profit of about 1.02 billion yuan to 1.12 billion yuan in 2023, turning a year-on-year loss into a profit; shareholders of Innovation Qizhi promised not to reduce their holdings after the sales restriction period expires, involving 265 million H shares.
Peijia Medical-B (09996.HK)'s 2023 revenue increased by about 71.5% — 79.4%
Gelonghui, January 25 | Peijia Medical-B (09996.HK) announced that for the year ended December 31, 2023, the company's revenue was about 430.0-450.0 million yuan, an increase of about 71.5% to 79.4% over the previous year. The increase in revenue was mainly due to the following reasons: (i) accelerated commercialization of transcatheter aortic valve replacement products (including first-generation TaurusOne and second-generation recyclable TaurusElite) to further expand the Group's market share; (ii) the Group's existing neurointerventional products (including Tethys intermediate-guided guidance)
Peijia Medical-B (09996.HK) received an additional 1,000 shares of common stock by Zhang Yi, worth approximately US$651.7
On January 25, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 25, Zhang Yi increased her $1,000 common stock holdings of $Pegia Medical-B (09996.HK) with an average price of $0.6517 per share on January 22, worth about $651.7. After the increase in holdings, Zhang Yi's latest shareholding was 154 million shares, with a good position ratio of 22.65%. Additional Information: Box 27:1. Yi Zhang, Jinnius Drive Trust, Ping Ye Zhang, Hanlindale Tru
No Data